Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence
Recruitment status was: Recruiting
|Study Design:||Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Cross-Sectional
Time Perspective: Prospective
|Official Title:||Angiogenesis Markers in Primiparas Versus Multiparas: Relevance to Preeclampsia Incidence|
|Study Start Date:||November 2005|
Primiparity is one of the main risk factors for having preeclampsia during pregnancy. Recently, sFlt-1, soluble FMS-like tyrosine kinase-1, has been shown to be a major molecule involved in the pathogenesis of preeclampsia. Higher sFlt-1 mRNA, higher serum levels of sFlt-1 as well as lower PlGF, placental growth factor, have been found in preeclamptic patients.
We intend to check the angiogenesis profile of primiparas as compared to multiparas.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00262093
|Hadassah Medical Organization|
|Jerusalem, Israel, 91240|
|Principal Investigator:||Yuval Bdolah, MD, MSc||Hadassah-Hebrew University Medical School|